Abstract 194P
Background
γδ T cells are a small subset (0.5-5%) of peripheral blood T cells playing a key role in both defense against a wide range of pathogens and anticancer immunity. In recent years, Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell malignancies. Although primarily expressed in B-cell lineage cells, BTK expression has also been identified in other cell types. However, the role of BTK expression and the impact of BTK inhibitors on non-B cells, including γδ T cells, remain unclear.
Methods
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using density gradient centrifugation. Selective γδ T cell expansion was achieved by adding zoledronic acid and IL-2. On day 14 of culturing, ibrutinib, acalabrutinib, or zanubrutinib were introduced. After 48 hours of co-incubation, cytokine production and γδ T cell activation were assessed. To evaluate the impact of BTK inhibitors on γδ T cell activation, HMBPP or the CLL cell line Duller was used as stimulation agents. Cytokine production was evaluated by stimulating the cells with M. tuberculosis lysate, PHA, HMBPP, or anti-CD3 [OKT3], followed by cell permeabilization, staining with specific antibodies, and analysis using flow cytometry.
Results
Ibrutinib significantly reduced the production of IFN-γ and TNF-α by γδ T cells stimulated with HMBPP, but not with Duller cells. This suggests that TCR-independent stimulation pathways, such as through the NK family of receptors, may restore cytokine production to normal levels. No significant differences were found in the production of granzyme B, IL-6, IL-9, IL-10, or IL-17a. All inhibitors reduced the early activation of γδ T cells, as indicated by decreased CD69 expression, while having no effect on late-stage activation. Interestingly, this inhibitory effect was least pronounced with ibrutinib.
Conclusions
BTK inhibitors seem to modulate γδ T cell function, with their impact being pathway-specific and potentially partially reversible depending on the type of stimulation. Moreover, newer inhibitors appear to have a lesser impact on γδ T cells, likely due to their higher specificity for BTK. From an immunotherapeutic perspective, concomitant treatment with BTK inhibitors and in vitro expanded γδ T cells could be a viable option.
Legal entity responsible for the study
Medical University of Lublin.
Funding
DKMS Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract